Host: Darryl S. Chutka, M.D. 

Guest: Stephen Kopecky, M.D. 

One of the biggest surprises we’ve seen in medicine in the past several years has been the numerous health benefits realized from the GLP-1 agonists. Originally developed for the management of diabetes, they’ve shown significant potential to improve cardiovascular risks, beyond controlling blood glucose and lowering hemoglobin A1c. Several studies have shown reductions in cardiovascular events including MI, stroke as well as reducing overall cardiovascular death. What is the mechanism of action for these cardiovascular benefits? Are there any differences in the various GLP-1 medications available and who’s a candidate for a GLP-1 medication? I’ll get answers to all of these questions and more in this podcast as I speak with Dr. Stephen Kopecky, a preventive cardiologist at the Mayo Clinic. We’ll be discussing “GLP-1 Agonists and Reducing Cardiovascular Risk”. 

Rx for Weight Loss: A Closer Look Series | Mayo Clinic School of Continuous Professional Development 

Learn more at https://ce.mayo.edu/online-education/content/mayo-clinic-podcasts